Ventricular TachycardiaNCT00270933
MAVRIC VR ICD Registry
An observational study of Ventricular Tachycardia and Ventricular Fibrillation, run by Medtronic Cardiac Rhythm and Heart Failure at 91 sites in 2 countries.
Trial summary
The purpose of this registry is to collect information on the health status of patients receiving Marquis/Maximo VR Implantable Cardiac Defibrillators (ICDs), how the devices are being programmed and how this correlates to clinical patient outcome. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ventricular Tachycardia, Ventricular Fibrillation
- What is being tested?
- Registry
- Type of treatment
- Medical device
- How many people
- 742 participants
- Where
- 91 sitesin 2 countries
- Study dates
- Jan 2004to Dec 2005
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients 18 years of age or older
- Patients implanted with a new or replacement Marquis VR or Maximo VR ICD
Who cannot join
- Patients enrolled in a device study that affects treatment and/or programming
Trial locations and contacts
91 sites in 2 countries.
91 sites in 2 countries
United States81 sites
Study site
Albany, New York
Study site
Allentown, Pennsylvania
Study site
Ann Arbor, Michigan
Study site
Atlanta, Georgia
Study site
Augusta, Georgia
Study site
Bakersfield, California
Study site
Baltimore, Maryland
Study site
Banning, California
Study site
Birmingham, Alabama
Study site
Cape Girardeau, Missouri
Study site
Cedar Rapids, Iowa
Study site
Charlottesville, Virginia
Study site
Chattanooga, Tennessee
Study site
Chicago, Illinois
Study site
Cincinnati, Ohio
Study site
Cleveland, Ohio
Study site
Columbus, Ohio
Study site
Coon Rapids, Minnesota
Study site
Corpus Christi, Texas
Study site
Dallas, Texas
Study site
Davenport, Iowa
Study site
Decatur, Georgia
Study site
Englewood, New Jersey
Study site
Eugene, Oregon
Study site
Fort Worth, Texas
Study site
Fresno, California
Study site
Hershey, Pennsylvania
Study site
Hobart, Indiana
Study site
Houston, Texas
Study site
Huntington, New York
Study site
Indianapolis, Indiana
Study site
Jackson, Mississippi
Study site
Jacksonville, Florida
Study site
Joplin, Missouri
Study site
Kansas City, Kansas
Study site
Kansas City, Missouri
Study site
Knoxville, Tennessee
Study site
Lakeland, Florida
Study site
Las Vegas, Nevada
Study site
Lebanon, New Hampshire
Study site
Lexington, Kentucky
Study site
Little Rock, Arkansas
Study site
Littleton, Colorado
Study site
Marrero, Louisiana
Study site
Mayfield Hts, Ohio
Study site
Memphis, Tennessee
Study site
Miami Beach, Florida
Study site
Milwaukee, Wisconsin
Study site
Mission Viejo, California
Study site
Missoula, Montana
Study site
New Hyde Park, New York
Study site
New York, New York
Study site
Newark, Delaware
Study site
Odessa, Texas
Study site
Oklahoma City, Oklahoma
Study site
Owensboro, Kentucky
Study site
Philadelphia, Pennsylvania
Study site
Pinehurst, North Carolina
Study site
Pittsburgh, Pennsylvania
Study site
Port Charlotte, Florida
Study site
Portland, Oregon
Study site
Richmond, Virginia
Study site
Sacramento, California
Study site
Saint Cloud, Minnesota
Study site
Saint Joseph, Michigan
Study site
Salisbury, Maryland
Study site
San Diego, California
Study site
Southfield, Michigan
Study site
Spartanburg, South Carolina
Study site
St Louis, Missouri
Study site
St. Petersburg, Florida
Study site
Stanford, California
Study site
Syracuse, New York
Study site
Tacoma, Washington
Study site
Tulsa, Oklahoma
Study site
Tuscaloosa, Alabama
Study site
Tyler, Texas
Study site
Washington D.C., District of Columbia
Study site
Winston-Salem, North Carolina
Study site
Worcester, Massachusetts
Study site
Youngstown, Ohio
Canada10 sites
Study site
Edmonton, Alberta
Study site
Halifax, Nova Scotia
Study site
Kingston, Ontario
Study site
London, Ontario
Study site
Montreal, Quebec
Study site
Ottawa, Ontario
Study site
St. John's, Newfoundland and Labrador
Study site
Ste-Foy, Quebec
Study site
Toronto, Ontario
Study site
Victoria, British Columbia
About this study
Official title: Marquis/Maximo VR ICD Programming Practices Registry (MAVRIC VR ICD Registry)
The purpose of this registry is to collect information on the health status of patients receiving Marquis/Maximo VR Implantable Cardiac Defibrillators (ICDs), how the devices are being programmed and how this correlates to clinical patient outcome.
- Conditions
- Ventricular Tachycardia, Ventricular Fibrillation
- Being tested
- Registry
- Keywords
- defibrillators, LLECG, ventricular tachycardia, ventricular fibrillation
- Medical subject headings
- Tachycardia, Ventricular, Ventricular Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RegistryDevice
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Dec 2005 (estimated)
- Study startJan 2004
- Study completionDec 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ventricular TachycardiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 742 participants
Sponsor and investigators
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Medtronic
- Investigators
- George Klein, M.D., Principal investigator, London H.S.C. University Campus
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00270933
- Sponsor's protocol ID
- 232
- Status last verified
- Dec 2023
- First submitted
- 28 Dec 2005
- Last updated
- 21 Dec 2023
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Marquis/Maximo VR ICD Programming Practices Registry (MAVRIC VR ICD Registry)
- ClinicalTrials.gov ID
- NCT00270933
- Acronym / sponsor ID
- 232
- Conditions
- Ventricular Tachycardia, Ventricular Fibrillation
- Keywords
- defibrillators, LLECG, ventricular tachycardia, ventricular fibrillation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 742 participants
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart FailureIndustry (pharma, biotech, devices)
- Collaborators
- Medtronic
- Study start
- Jan 2004
- Study completion
- Dec 2005
- First posted
- 29 Dec 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this registry is to collect information on the health status of patients receiving Marquis/Maximo VR Implantable Cardiac Defibrillators (ICDs), how the devices are being programmed and how this correlates to clinical patient outcome.
Study design
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Patients 18 years of age or older
- Patients implanted with a new or replacement Marquis VR or Maximo VR ICD
Key exclusion criteria (1 listed)
- Patients enrolled in a device study that affects treatment and/or programming
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Registry | Device | – |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Dec 2023.
Related trials for Ventricular Tachycardia
RecruitingPhase 1
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Catecholaminergic Polymorphic Ventricular Tachycardia
Recruiting
Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT)
Ventricular Tachycardia
Active, not recruiting
Combined Pulsed Field and Radiofrequency Energy for Ablation of Ventricular Tachycardia
Ventricular Tachycardia (V-Tach)
Recruiting
SPIKE FLOW Endocardial Lead Safety and Performance Study
Acute Myocardial Infarction (AMI), Asystole
RecruitingObservational study
The Multicenter Cardiology Monitoring Platform Registry
Heart Failure, Cardiomyopathies
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
George Klein, M.D. principal investigator
London H.S.C. University Campus
91 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ventricular Tachycardia and Ventricular Fibrillation, run by Medtronic Cardiac Rhythm and Heart Failure at 91 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 91 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Dec 2023; AzTrials last refreshed its copy on 27 Oct 2026.